Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
...
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2021-08-10
- Target Recruit Count
- 1505
- Registration Number
- NCT04999293
- Locations
- 🇨🇳
The First Affiliated Hospital of Dalian Medical University, Dalian, China
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Medical University of Gdansk
- Target Recruit Count
- 2230
- Registration Number
- NCT04695106
- Locations
- 🇵🇱
Cardiac lntensive Care Unit, First Department of Cardiology, University Clinical Centre in Gdańsk, Gdańsk, Pomorskie, Poland
Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
- Target Recruit Count
- 1900
- Registration Number
- NCT04630288
- Locations
- 🇪🇸
Hospital Universitario Virgen Macarena, Sevilla, Spain
🇪🇸Fundación Pública Progreso y Salud, Sevilla, Spain
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 103
- Registration Number
- NCT04588727
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- University of Zagreb
- Target Recruit Count
- 120
- Registration Number
- NCT04369534
- Locations
- 🇭🇷
Uhiversity hospital Center Zagreb, Zagreb, Croatia
A Study of Low Dose vs Standard Ticagrelor on Platelet Function After Intervention for Acute Coronary Syndrome in Senior Patients
- Conditions
- Interventions
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Shanghai Tong Ren Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04307485
- Locations
- 🇨🇳
shanghai Tongren hospital, Shanghai, Shanghai, China
A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients
- Conditions
- Interventions
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Shanghai Tong Ren Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04307511
- Locations
- 🇨🇳
shanghai Tongren hospital, Shanghai, China
Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT04293172
Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Fu Wai Hospital, Beijing, China
- Target Recruit Count
- 1220
- Registration Number
- NCT04240834
- Locations
- 🇨🇳
Fuwai Hospital, Beijing, Beijing, China
The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- The University of The West Indies
- Target Recruit Count
- 25
- Registration Number
- NCT04206176
- Locations
- 🇹🇹
The University of the West Indies, Saint Augustine, North, Trinidad and Tobago
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.